Showing results (41-50 of 67) with videos related to

Sort By:
Pageof 7
Bioactive Materials|June 19, 2023
All-in-one glycol chitosan nanoparticles for co-delivery of doxorubicin and anti-PD-L1 peptide in cancer immunotherapySukyung Song, Man Kyu Shim, Suah Yang, et al.
Biomaterials Research|May 26, 2023
Liposomes targeting the cancer cell-exposed receptor, claudin-4, for pancreatic cancer chemotherapyChaeeun Bang, Min Gyu Park, In Kyung Cho, et al.
Angewandte Chemie (International Ed. in English)|October 21, 2016
Cathepsin B-Specific Metabolic Precursor for In Vivo Tumor-Specific Fluorescence ImagingMan Kyu Shim, Hong Yeol Yoon, Ju Hee Ryu, et al.
Biomaterials|October 29, 2020
Predicting in vivo therapeutic efficacy of bioorthogonally labeled endothelial progenitor cells in hind limb ischemia models via non-invasive fluorescence molecular tomographySeungho Lim, Hong Yeol Yoon, Soon-Jung Park, et al.
Molecular Pharmaceutics|February 14, 2017
Artificial Chemical Reporter Targeting Strategy Using Bioorthogonal Click Reaction for Improving Active-Targeting Efficiency of TumorHong Yeol Yoon, Min Lee Shin, Man Kyu Shim, et al.
Small (Weinheim an Der Bergstrasse, Germany)|July 22, 2025
Targeted Delivery of miR-34a via Anti-CD47 Antibody Conjugates for Enhanced Cancer Immunotherapy in Triple Negative Breast CancerYoungri Ryu, Eun Hye Kim, Hochung Jang, et al.
Pharmaceutics|December 2, 2020
Doxorubicin-Loaded PLGA Nanoparticles for Cancer Therapy: Molecular Weight Effect of PLGA in Doxorubicin Release for Controlling Immunogenic Cell DeathYongwhan Choi, Hong Yeol Yoon, Jeongrae Kim, et al.
Biomaterials|September 26, 2022
Comparative study of cathepsin B-cleavable linkers for the optimal design of cathepsin B-specific doxorubicin prodrug nanoparticles for targeted cancer therapyNayeon Shim, Seong Ik Jeon, Suah Yang, et al.
Theranostics|January 8, 2025
Drug repositioning of mesalamine via supramolecular nanoassembly for the treatment of drug-induced acute liver failureByeongmin Park, Eun Hye Kim, Hochung Jang, et al.
Pharmaceutics|March 26, 2022
Sustained and Long-Term Release of Doxorubicin from PLGA Nanoparticles for Eliciting Anti-Tumor Immune ResponsesJeongrae Kim, Yongwhan Choi, Suah Yang, et al.
Pageof 7